IP Library Granted Patent US 10,415,041
Granted Patent B2
US 10,415,041 · App. 15/893,532 · Granted Sep 17, 2019

Functional ligands to target molecules

Inventor: George W. Jackson (Pearland, TX)
Assignee: Base Pair Biotechnologies, Inc.
C12N15/115C12N15/1048C12N2310/16C12N2330/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,415,041
App. No.
15/893,532
Granted
Sep 17, 2019
Kind
B2
Abstract

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as amino acids, such as citrulline, and to target molecules such as crystallin or its subunits, such as alpha crystallin B-chain (CRYAB).

Claims (10)

1. An artificial ligand binding to citrulline comprising a non-naturally occurring nucleic acid sequence of under 40 nucleotides in length having substantial homology and greater than 80% sequence identity to a sequence selected from the group consisting of SEQ IDs 2-10.

2. The artificial ligand of claim 1 wherein at least one nucleotide is substituted with a non-natural analog.

3. The artificial ligand of claim 1 further comprising an appended 5′-sequence selected from the group consisting of SEQ IDs 231-232.

4. The artificial ligand of claim 1 further comprising an appended 3′-sequence selected from the group consisting of SEQ IDs 231-232.

5. The artificial ligand of claim 1 further comprising an appended 5′-sequence and an appended 3′-sequence selected from the group consisting of SEQ IDs 231-232.

6. An artificial ligand binding to citrulline consisting essentially of a non-naturally occurring nucleic acid sequence having the sequence selected from the group consisting of SEQ IDs 1-10.

7. The artificial ligand of claim 6 wherein at least one nucleotide is substituted with a non-natural analog.

8. The artificial ligand of claim 6 wherein said non-naturally occurring nucleic acid sequence is appended with a 5′-sequence selected from the group consisting of SEQ IDs 231-232.

9. The artificial ligand of claim 6 wherein said non-naturally occurring nucleic acid sequence is appended with a 3′-sequence selected from the group consisting of SEQ IDs 231-232.

10. The artificial ligand of claim 6 wherein said non-naturally occurring nucleic acid sequence is appended with a 5′-sequence and a 3′-sequence selected from the group consisting of SEQ IDs 231-232.

Continuity (3)
Provisional Application 62460786 · Feb 18, 2017
Provisional Application 62456847 · Feb 9, 2017
Related Publication 20180237782A1 · Aug 23, 2018